Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
Executive Summary
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
You may also be interested in...
Pfizer/Sanofi speculation
Rumors are cropping up regarding potential acquisition of Sanofi-Aventis, or at least a stake in the company, by Pfizer - which has a hefty amount of cash on hand and a pipeline to fill. Sanofi has been the subject of various acquisition rumors, including reports that the company was considering acquiring Plavix (clopidogrel) and Avapro (irbesartan) marketing partner Bristol-Myers Squibb (1"The Pink Sheet" Aug. 14, 2006, p. 3). Merging might not be in the best interest of either company, as both firms' biggest products lose exclusivity in the same timeframe: Pfizer's Lipitor (atorvastatin) in 2010 and Plavix in 2011. Pfizer's recently announced R&D strategy includes working to secure external opportunities in targeted areas through acquisitions, licensing and development, joint venture and alliances and other collaborative agreements (2"The Pink Sheet" Oct. 8, 2007, p. 3)...
Pfizer/Sanofi speculation
Rumors are cropping up regarding potential acquisition of Sanofi-Aventis, or at least a stake in the company, by Pfizer - which has a hefty amount of cash on hand and a pipeline to fill. Sanofi has been the subject of various acquisition rumors, including reports that the company was considering acquiring Plavix (clopidogrel) and Avapro (irbesartan) marketing partner Bristol-Myers Squibb (1"The Pink Sheet" Aug. 14, 2006, p. 3). Merging might not be in the best interest of either company, as both firms' biggest products lose exclusivity in the same timeframe: Pfizer's Lipitor (atorvastatin) in 2010 and Plavix in 2011. Pfizer's recently announced R&D strategy includes working to secure external opportunities in targeted areas through acquisitions, licensing and development, joint venture and alliances and other collaborative agreements (2"The Pink Sheet" Oct. 8, 2007, p. 3)...
Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan
Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13